Möchten Sie immer auf dem neuesten Stand bleiben?

Quoin advances its U.S. patent protection with allowed claims supporting QRX003's investigational approach to treating Netherton Syndrome.

Neutra Corp’s Subsidiary Neutra Life Sciences Executes New Women’s Health Joint Venture and Expands Trial Portfolio

Under Veripure, Provectus is supplying qualified medical researchers with the same pharmaceutical grade rose bengal sodium API used in clinical trials.Veripure is also a quality benchmark,...

Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome.

VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on skin health and longevity, today announced...

The analysis explores how AI-driven innovations are transforming skin disease detection, treatment planning and aesthetic dermatology procedures.

Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients...

KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the...

The report tracks key market indicators, sustainability trends, investment flows and innovation patterns shaping the global life sciences landscape.

Schaumburg, IL, May 26, 2026 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to introduce a refreshed format for its DermSugery Digest Podcast. Led by host Naomi...